Epigallocatechin-3-gallate prevents systemic inflammation-induced memory deficiency and amyloidogenesis via its anti-neuroinflammatory properties

Journal of Nutritional Biochemistry

Volumn 24, Issue 1, 2013, Pages 298-310

  Lee, Young Jung ^a   Choi, Dong Young ^a   Yun, Yeo Pyo ^a   Han, Sang Bae ^a   Oh, Ki Wan ^a   Hong, Jin Tae ^a  

^a Chungbuk National University   (South Korea)

Author keywords

Alzheimer's disease; Amyloid beta; EGCG; Green tea; Lipopolysaccharide

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE 1; COLONY STIMULATING FACTOR 1; CYCLOOXYGENASE 2; EPIGALLOCATECHIN GALLATE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 16; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; ASTROCYTE; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG MECHANISM; MEMORY DISORDER; MOUSE; NERVE CELL NECROSIS; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PROTEIN EXPRESSION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ASTROCYTES; BEHAVIOR, ANIMAL; CATECHIN; CELLS, CULTURED; CYCLOOXYGENASE 2; CYTOKINES; DISEASE MODELS, ANIMAL; INFLAMMATION; LIPOPOLYSACCHARIDES; MALE; MEMORY DISORDERS; MICE; MICE, INBRED ICR; NEURONS; NITRIC OXIDE SYNTHASE TYPE II; PEPTIDE FRAGMENTS; RATS;

MUS;

EID: 84870456663     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2012.06.011     Document Type: Article

References (112)

1. Blennow K., de Leon M.J., Zetterberg H. Alzheimer's disease. Lancet 2006, 368:387-403.
2. Ferri C.P., Sousa R., Albanese E., Ribeiro W.S., Honyashiki M. World alzheimer report 2009 - executive summary 2009, 1-22. Alzheimer's disease international, London. M. Prince, J. Jackson (Eds.).
3. Mattson M.P., Maudsley S., Martin B. A neural signaling triumvirate that influences ageing and age-related disease: insulin/IGF-1, BDNF and serotonin. Ageing Res Rev 2004, 3:445-464.
4. Pratico D., Trojanowski J.Q. Inflammatory hypotheses: novel mechanisms of Alzheimer's neurodegeneration and new therapeutic targets?. Neurobiol Aging 2000, 21:441-445. [discussion 51-3].
5. Maeda J., Ji B., Irie T., Tomiyama T., Maruyama M., Okauchi T., et al. Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. J Neurosci 2007, 27:10957-10968.
6. Xu F., Grande A.M., Robinson J.K., Previti M.L., Vasek M., Davis J., et al. Early-onset subicular microvascular amyloid and neuroinflammation correlate with behavioral deficits in vasculotropic mutant amyloid beta-protein precursor transgenic mice. Neuroscience 2007, 146:98-107.
7. Nichol K.E., Poon W.W., Parachikova A.I., Cribbs D.H., Glabe C.G., Cotman C.W. Exercise alters the immune profile in Tg2576 Alzheimer mice toward a response coincident with improved cognitive performance and decreased amyloid. J Neuroinflammation 2008, 5:13.
8. Fang F., Lue L.F., Yan S., Xu H., Luddy J.S., Chen D., et al. RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease. FASEB J 2010, 24:1043-1055.
9. McGeer E.G., McGeer P.L. Inflammatory processes in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27:741-749.
10. Guo J.T., Yu J., Grass D., de Beer F.C., Kindy M.S. Inflammation-dependent cerebral deposition of serum amyloid a protein in a mouse model of amyloidosis. J Neurosci 2002, 22:5900-5909.
11. Simic G., Lucassen P.J., Krsnik Z., Kruslin B., Kostovic I., Winblad B., et al. nNOS expression in reactive astrocytes correlates with increased cell death related DNA damage in the hippocampus and entorhinal cortex in Alzheimer's disease. Exp Neurol 2000, 165:12-26.
12. Bluthe R.M., Laye S., Michaud B., Combe C., Dantzer R., Parnet P. Role of interleukin-1beta and tumour necrosis factor-alpha in lipopolysaccharide-induced sickness behaviour: a study with interleukin-1 type I receptor-deficient mice. Eur J Neurosci 2000, 12:4447-4456.
13. Qin L., Wu X., Block M.L., Liu Y., Breese G.R., Hong J.S., et al. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 2007, 55:453-462.
14. Mouton P.R., Kelley-Bell B., Tweedie D., Spangler E.L., Perez E., Carlson O.D., et al. The effects of age and lipopolysaccharide (LPS)-mediated peripheral inflammation on numbers of central catecholaminergic neurons. Neurobiol Aging 2012, 33:423.e27-423.e36.
15. Erickson M.A., Banks W.A. Cytokine and chemokine responses in serum and brain after single and repeated injections of lipopolysaccharide: multiplex quantification with path analysis. Brain Behav Immun 2011, 25:1637-1648.
16. Sastre M., Dewachter I., Landreth G.E., Willson T.M., Klockgether T., van Leuven F., et al. Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J Neurosci 2003, 23:9796-9804.
17. Vassar R. The beta-secretase, BACE: a prime drug target for Alzheimer's disease. J Mol Neurosci 2001, 17:157-170.
18. Jaeger L.B., Dohgu S., Sultana R., Lynch J.L., Owen J.B., Erickson M.A., et al. Lipopolysaccharide alters the blood-brain barrier transport of amyloid beta protein: a mechanism for inflammation in the progression of Alzheimer's disease. Brain Behav Immun 2009, 23:507-517.
19. Lee J.W., Lee Y.K., Yuk D.Y., Choi D.Y., Ban S.B., Oh K.W., et al. Neuro-inflammation induced by lipopolysaccharide causes cognitive impairment through enhancement of beta-amyloid generation. J Neuroinflammation 2008, 5:37.
20. Breitner J.C., Baker L.D., Montine T.J., Meinert C.L., Lyketsos C.G., Ashe K.H., et al. Extended results of the Alzheimer's disease anti-inflammatory prevention trial. Alzheimers Dement 2011, 7:402-411.
21. Singh M., Arseneault M., Sanderson T., Murthy V., Ramassamy C. Challenges for research on polyphenols from foods in Alzheimer's disease: bioavailability, metabolism, and cellular and molecular mechanisms. J Agric Food Chem 2008, 56:4855-4873.
22. Rezai-Zadeh K., Shytle D., Sun N., Mori T., Hou H., Jeanniton D., et al. Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J Neurosci 2005, 25:8807-8814.
23. Rezai-Zadeh K., Arendash G.W., Hou H., Fernandez F., Jensen M., Runfeldt M., et al. Green tea epigallocatechin-3-gallate (EGCG) reduces beta-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice. Brain Res 2008, 1214:177-187.
24. Mandel S., Weinreb O., Amit T., Youdim M.B. Cell signaling pathways in the neuroprotective actions of the green tea polyphenol (-)-epigallocatechin-3-gallate: implications for neurodegenerative diseases. J Neurochem 2004, 88:1555-1569.
25. Antonio A.M., Druse M.J. Antioxidants prevent ethanol-associated apoptosis in fetal rhombencephalic neurons. Brain Res 2008, 1204:16-23.
26. Cho H.S., Kim S., Lee S.Y., Park J.A., Kim S.J., Chun H.S. Protective effect of the green tea component, L-theanine on environmental toxins-induced neuronal cell death. Neurotoxicology 2008, 29:656-662.
27. Okello E.J., Savelev S.U., Perry E.K. vitro anti-beta-secretase and dual anti-cholinesterase activities of Camellia sinensis L. (tea) relevant to treatment of dementia. Phytother Res 2004, 18:624-627.
28. Lee Y.K., Yuk D.Y., Lee J.W., Lee S.Y., Ha T.Y., Oh K.W., et al. (-)-Epigallocatechin-3-gallate prevents lipopolysaccharide-induced elevation of beta-amyloid generation and memory deficiency. Brain Res 2009, 1250:164-174.
29. Lee J.W., Lee Y.K., Ban J.O., Ha T.Y., Yun Y.P., Han S.B., et al. Green tea (-)-epigallocatechin-3-gallate inhibits beta-amyloid-induced cognitive dysfunction through modification of secretase activity via inhibition of ERK and NF-kappaB pathways in mice. J Nutr 2009, 139:1987-1993.
30. Muramatsu K., Fukuyo M., Hara Y. Effect of green tea catechins on plasma cholesterol level in cholesterol-fed rats. J Nutr Sci Vitaminol (Tokyo). 1986, 32:613-622.
31. Rietveld A., Wiseman S. Antioxidant effects of tea: evidence from human clinical trials. J Nutr 2003, 133:3285S-3292S.
32. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 1984, 11:47-60.
33. Lee S.M., Nguyen T.H., Park M.H., Kim K.S., Cho K.J., Moon D.C., et al. EPO receptor-mediated ERK kinase and NF-kappaB activation in erythropoietin-promoted differentiation of astrocytes. Biochem Biophys Res Commun 2004, 320:1087-1095.
34. Park K.S., Lee R.D., Kang S.K., Han S.Y., Park K.L., Yang K.H., et al. Neuronal differentiation of embryonic midbrain cells by upregulation of peroxisome proliferator-activated receptor-gamma via the JNK-dependent pathway. Exp Cell Res 2004, 297:424-433.
35. Choi S.H., Joe E.H., Kim S.U., Jin B.K. Thrombin-induced microglial activation produces degeneration of nigral dopaminergic neurons in vivo. J Neurosci 2003, 23:5877-5886.
36. Nguyen H.N., Lee M.S., Hwang D.Y., Kim Y.K., Yoon do Y., Lee J.W., et al. Mutant presenilin 2 increased oxidative stress and p53 expression in neuronal cells. Biochem Biophys Res Commun 2007, 357:174-180.
37. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M., et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000, 21:383-421.
38. McGeer P.L., McGeer E.G. NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol Aging 2006, 28:639-647.
39. Veerhuis R. Histological and direct evidence for the role of complement in the neuroinflammation of AD. Curr Alzheimer Res 2011, 8:34-58.
40. Heneka M.T., Kummer M.P., Weggen S., Bulic B., Multhaup G., Munter L., et al. Molecular mechanisms and therapeutic application of NSAIDs and derived compounds in Alzheimer's disease. Curr Alzheimer Res 2011, 8:115-131.
41. Mastronardi C.A., Licinio J., Wong M.L. Candidate biomarkers for systemic inflammatory response syndrome and inflammation: a pathway for novel translational therapeutics. Neuroimmunomodulation 2010, 17:359-368.
42. Hughes M.M., Field R.H., Perry V.H., Murray C.L., Cunningham C. Microglia in the degenerating brain are capable of phagocytosis of beads and of apoptotic cells, but do not efficiently remove PrPSc, even upon LPS stimulation. Glia 2010, 58:2017-2030.
43. Bay-Richter C., Janelidze S., Hallberg L., Brundin L. Changes in behaviour and cytokine expression upon a peripheral immune challenge. Behav Brain Res 2011, 222:193-199.
44. Sheng J.G., Bora S.H., Xu G., Borchelt D.R., Price D.L., Koliatsos V.E. Lipopolysaccharide-induced-neuroinflammation increases intracellular accumulation of amyloid precursor protein and amyloid beta peptide in APPswe transgenic mice. Neurobiol Dis 2003, 14:133-145.
45. Michelucci A., Heurtaux T., Grandbarbe L., Morga E., Heuschling P. Characterization of the microglial phenotype under specific pro-inflammatory and anti-inflammatory conditions: effects of oligomeric and fibrillar amyloid-beta. J Neuroimmunol 2009, 210:3-12.
46. McAlpine F.E., Lee J.K., Harms A.S., Ruhn K.A., Blurton-Jones M., Hong J., et al. Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. Neurobiol Dis 2009, 34:163-177.
47. Scholtzova H., Kascsak R.J., Bates K.A., Boutajangout A., Kerr D.J., Meeker H.C., et al. Induction of toll-like receptor 9 signaling as a method for ameliorating Alzheimer's disease-related pathology. J Neurosci 2009, 29:1846-1854.
48. Hensley K., Maidt M.L., Yu Z., Sang H., Markesbery W.R., Floyd R.A. Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation. J Neurosci 1998, 18:8126-8132.
49. Paris D., Townsend K.P., Obregon D.F., Humphrey J., Mullan M. Pro-inflammatory effect of freshly solubilized beta-amyloid peptides in the brain. Prostaglandins Other Lipid Mediat 2002, 70:1-12.
50. Rodriguez J.J., Olabarria M., Chvatal A., Verkhratsky A. Astroglia in dementia and Alzheimer's disease. Cell Death Differ 2009, 16:378-385.
51. Blasko I., Stampfer-Kountchev M., Robatscher P., Veerhuis R., Eikelenboom P., Grubeck-Loebenstein B. How chronic inflammation can affect the brain and support the development of Alzheimer's disease in old age: the role of microglia and astrocytes. Aging Cell 2004, 3:169-176.
52. Cho H.J., Kim S.K., Jin S.M., Hwang E.M., Kim Y.S., Huh K., et al. IFN-gamma-induced BACE1 expression is mediated by activation of JAK2 and ERK1/2 signaling pathways and direct binding of STAT1 to BACE1 promoter in astrocytes. Glia 2007, 55:253-262.
53. Gunasingh M.J., Philip J.E., Ashok B.S., Kirubagaran R., Jebaraj W.C., Davis G.D., et al. Melatonin prevents amyloid protofibrillar induced oxidative imbalance and biogenic amine catabolism. Life Sci 2008, 83:96-102.
54. Schubert D., Soucek T., Blouw B. The induction of HIF-1 reduces astrocyte activation by amyloid beta peptide. Eur J Neurosci 2009, 29:1323-1334.
55. Nadler Y., Alexandrovich A., Grigoriadis N., Hartmann T., Rao K.S., Shohami E., et al. Increased expression of the gamma-secretase components presenilin-1 and nicastrin in activated astrocytes and microglia following traumatic brain injury. Glia 2008, 56:552-567.
56. Hartlage-Rubsamen M., Zeitschel U., Apelt J., Gartner U., Franke H., Stahl T., et al. Astrocytic expression of the Alzheimer's disease beta-secretase (BACE1) is stimulus-dependent. Glia 2003, 41:169-179.
57. Verdier Y., Zarandi M., Penke B. Amyloid beta-peptide interactions with neuronal and glial cell plasma membrane: binding sites and implications for Alzheimer's disease. J Pept Sci 2004, 10:229-248.
58. Lue L.F., Walker D.G., Rogers J. Modeling microglial activation in Alzheimer's disease with human postmortem microglial cultures. Neurobiol Aging 2001, 22:945-956.
59. Laske C., Stransky E., Hoffmann N., Maetzler W., Straten G., Eschweiler G.W., et al. Macrophage colony-stimulating factor (M-CSF) in plasma and CSF of patients with mild cognitive impairment and Alzheimer's disease. Curr Alzheimer Res 2010, 7:409-414.
60. Murphy G.M., Zhao F., Yang L., Cordell B. Expression of macrophage colony-stimulating factor receptor is increased in the AbetaPP(V717F) transgenic mouse model of Alzheimer's disease. Am J Pathol 2000, 157:895-904.
61. Murphy G.M., Yang L., Cordell B. Macrophage colony-stimulating factor augments beta-amyloid-induced interleukin-1, interleukin-6, and nitric oxide production by microglial cells. J Biol Chem 1998, 273:20967-20971.
62. Mitrasinovic O.M., Perez G.V., Zhao F., Lee Y.L., Poon C., Murphy G.M. Overexpression of macrophage colony-stimulating factor receptor on microglial cells induces an inflammatory response. J Biol Chem 2001, 276:30142-30149.
63. O'Sullivan J.B., Ryan K.M., Harkin A., Connor T.J. Noradrenaline reuptake inhibitors inhibit expression of chemokines IP-10 and RANTES and cell adhesion molecules VCAM-1 and ICAM-1 in the CNS following a systemic inflammatory challenge. J Neuroimmunol 2010, 220:34-42.
64. Wang G., Namura S. Effects of chronic systemic treatment with peroxisome proliferator-activated receptor alpha activators on neuroinflammation induced by intracerebral injection of lipopolysaccharide in adult mice. Neurosci Res 2011, 70:230-237.
65. Verbeek M.M., Otte-Holler I., Wesseling P., Ruiter D.J., de Waal R.M. Differential expression of intercellular adhesion molecule-1 (ICAM-1) in the A beta-containing lesions in brains of patients with dementia of the Alzheimer type. Acta Neuropathol 1996, 91:608-615.
66. Eikelenboom P., Zhan S.S., Kamphorst W., van der Valk P., Rozemuller J.M. Cellular and substrate adhesion molecules (integrins) and their ligands in cerebral amyloid plaques in Alzheimer's disease. Virchows Arch 1994, 424:421-427.
67. Apelt J., Leßig J., Schliebs R. [beta]-Amyloid-associated expression of intercellular adhesion molecule-1 in brain cortical tissue of transgenic Tg2576 mice. Neurosci Lett 2002, 329:111-115.
68. Gonzalez-Velasquez F.J., Kotarek J.A., Moss M.A. Soluble aggregates of the amyloid-beta protein selectively stimulate permeability in human brain microvascular endothelial monolayers. J Neurochem 2008, 107:466-477.
69. Cruikshank W.W., Long A., Tarpy R.E., Kornfeld H., Carroll M.P., Teran L., et al. Early identification of interleukin-16 (lymphocyte chemoattractant factor) and macrophage inflammatory protein 1 alpha (MIP1 alpha) in bronchoalveolar lavage fluid of antigen-challenged asthmatics. Am J Respir Cell Mol Biol 1995, 13:738-747.
70. Schluesener H.J., Seid K., Kretzschmar J., Meyermann R. Leukocyte chemotactic factor, a natural ligand to CD4, is expressed by lymphocytes and microglial cells of the MS plaque. J Neurosci Res 1996, 44:606-611.
71. Mathy N.L., Scheuer W., Lanzendorfer M., Honold K., Ambrosius D., Norley S., et al. Interleukin-16 stimulates the expression and production of pro-inflammatory cytokines by human monocytes. Immunology 2000, 100:63-69.
72. Lipton P. Ischemic cell death in brain neurons. Physiol Rev 1999, 79:1431-1568.
73. Mattson M.P. ER calcium and Alzheimer's disease: in a state of flux. Sci Signal 2010, 3:10.
74. Zara S., Rapino M., Sozio P., Di Stefano A., Nasuti C., Cataldi A. Ibuprofen and lipoic acid codrug 1 control Alzheimer's disease progression by down-regulating protein kinase C epsilon-mediated metalloproteinase 2 and 9 levels in beta-amyloid infused Alzheimer's disease rat model. Brain Res 2011, 1412:79-87.
75. Motta M., Imbesi R., Di Rosa M., Stivala F., Malaguarnera L. Altered plasma cytokine levels in Alzheimer's disease: correlation with the disease progression. Immunol Lett 2007, 114:46-51.
76. Di Rosa M., Dell'Ombra N., Zambito A.M., Malaguarnera M., Nicoletti F., Malaguarnera L. Chitotriosidase and inflammatory mediator levels in Alzheimer's disease and cerebrovascular dementia. Eur J Neurosci 2006, 23:2648-2656.
77. Morales I., Farias G., Maccioni R.B. Neuroimmunomodulation in the pathogenesis of Alzheimer's disease. Neuroimmunomodulation 2010, 17:202-204.
78. Halleskog C., Mulder J., Dahlstrom J., Mackie K., Hortobagyi T., Tanila H., et al. WNT signaling in activated microglia is proinflammatory. Glia 2011, 59:119-131.
79. Lee Y.J., Choi D.Y., Choi I.S., Kim K.H., Kim Y.H., Kim H.M., et al. Inhibitory effect of 4-O-methylhonokiol on lipopolysaccharide-induced neuroinflammation, amyloidogenesis and memory impairment via inhibition of nuclear factor-kappaB in vitro and in vivo models. J Neuroinflammation 2012, 9:35.
80. Lin G.H., Lee Y.J., Choi D.Y., Han S.B., Jung J.K., Hwang B.Y., et al. Anti-amyloidogenic effect of thiacremonone through anti-inflamation in vitro and in vivo models. J Alzheimers Dis 2012, 29:659-676.
81. Lee Y.J., Choi D.Y., Lee Y.K., Lee Y.M., Han S.B., Kim Y.H., et al. 4-O-methylhonokiol prevents memory impairment in the Tg2576 transgenic mice model of Alzheimer's disease via regulation of beta-secretase activity. J Alzheimers Dis 2012, 29:677-690.
82. Li R., Huang Y.G., Fang D., Le W.D. (-)-Epigallocatechin gallate inhibits lipopolysaccharide-induced microglial activation and protects against inflammation-mediated dopaminergic neuronal injury. J Neurosci Res 2004, 78:723-731.
83. Xu Z., Chen S., Li X., Luo G., Li L., Le W. Neuroprotective effects of (-)-epigallocatechin-3-gallate in a transgenic mouse model of amyotrophic lateral sclerosis. Neurochem Res 2006, 31:1263-1269.
84. Jang S., Jeong H.S., Park J.S., Kim Y.S., Jin C.Y., Seol M.B., et al. Neuroprotective effects of (-)-epigallocatechin-3-gallate against quinolinic acid-induced excitotoxicity via PI3K pathway and NO inhibition. Brain Res 2010, 1313:25-33.
85. Li R., Peng N., Du F., Li X.P., Le W.D. Epigallocatechin gallate protects dopaminergic neurons against 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity by inhibiting microglial cell activation. Nan Fang Yi Ke Da Xue Xue Bao 2006, 26:376-380.
86. Franco E.C.S., Cardoso M.M., Gouvêia A., Pereira A., Gomes-Leal W. Modulation of microglial activation enhances neuroprotection and functional recovery derived from bone marrow mononuclear cell transplantation after cortical ischemia. Neurosci Res 2012, 73:122-132.
87. Ortega F.J., Gimeno-Bayon J., Espinosa-Parrilla J.F., Carrasco J.L., Batlle M., Pugliese M., et al. ATP-dependent potassium channel blockade strengthens microglial neuroprotection after hypoxia-ischemia in rats. Exp Neurol 2012, 235:282-296.
88. Yenari M.A., Kauppinen T.M., Swanson R.A. Microglial activation in stroke: therapeutic targets. Neurotherapeutics 2010, 7:378-391.
89. Lambert J.D., Elias R.J. The antioxidant and pro-oxidant activities of green tea polyphenols: a role in cancer prevention. Arch Biochem Biophys 2010, 501:65-72.
90. Chow H.H., Cai Y., Hakim I.A., Crowell J.A., Shahi F., Brooks C.A., et al. Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin Cancer Res 2003, 9:3312-3319.
91. Isbrucker R.A., Bausch J., Edwards J.A., Wolz E. Safety studies on epigallocatechin gallate (EGCG) preparations. Part 1: genotoxicity. Food Chem Toxicol 2006, 44:626-635.
92. Isbrucker R.A., Edwards J.A., Wolz E., Davidovich A., Bausch J. Safety studies on epigallocatechin gallate (EGCG) preparations. Part 2: dermal, acute and short-term toxicity studies. Food Chem Toxicol 2006, 44:636-650.
93. Isbrucker R.A., Edwards J.A., Wolz E., Davidovich A., Bausch J. Safety studies on epigallocatechin gallate (EGCG) preparations. Part 3: teratogenicity and reproductive toxicity studies in rats. Food Chem Toxicol 2006, 44:651-661.
94. Vignes M., Maurice T., Lante F., Nedjar M., Thethi K., Guiramand J., et al. Anxiolytic properties of green tea polyphenol (-)-epigallocatechin gallate (EGCG). Brain Res 2006, 1110:102-115.
95. Lambert J.D., Kennett M.J., Sang S., Reuhl K.R., Ju J., Yang C.S. Hepatotoxicity of high oral dose (-)-epigallocatechin-3-gallate in mice. Food Chem Toxicol 2010, 48:409-416.
96. Mereles D., Hunstein W. Epigallocatechin-3-gallate (EGCG) for clinical trials: more pitfalls than promises?. Int J Mol Sci 2011, 12:5592-5603.
97. Fujiki H., Suganuma M., Okabe S., Sueoka E., Suga K., Imai K., et al. Mechanistic findings of green tea as cancer preventive for humans. Proc Soc Exp Biol Med 1999, 220:225-228.
98. Hsu C.H., Liao Y.L., Lin S.C., Tsai T.H., Huang C.J., Chou P. Does supplementation with green tea extract improve insulin resistance in obese type 2 diabetics? A randomized, double-blind, and placebo-controlled clinical trial. Altern Med Rev 2011, 16:157-163.
99. Ishii T., Ichikawa T., Minoda K., Kusaka K., Ito S., Suzuki Y., et al. Human serum albumin as an antioxidant in the oxidation of (-)-epigallocatechin gallate: participation of reversible covalent binding for interaction and stabilization. Biosci Biotechnol Biochem 2011, 75:100-106.
100. Peters C.M., Green R.J., Janle E.M., Ferruzzi M.G. Formulation with ascorbic acid and sucrose modulates catechin bioavailability from green tea. Food Res Int 2010, 43:95-102.
101. Giunta B., Hou H., Zhu Y., Salemi J., Ruscin A., Shytle R.D., et al. Fish oil enhances anti-amyloidogenic properties of green tea EGCG in Tg2576 mice. Neurosci Lett 2010, 471:134-138.
102. Lambert J.D., Hong J., Kim D.H., Mishin V.M., Yang C.S. Piperine enhances the bioavailability of the tea polyphenol (-)-epigallocatechin-3-gallate in mice. J Nutr 2004, 134:1948-1952.
103. Huo C., Wan S.B., Lam W.H., Li L., Wang Z., Landis-Piwowar K.R., et al. The challenge of developing green tea polyphenols as therapeutic agents. Inflammopharmacology 2008, 16:248-252.
104. Lambert J.D., Sang S., Hong J., Kwon S.J., Lee M.J., Ho C.T., et al. Peracetylation as a means of enhancing in vitro bioactivity and bioavailability of epigallocatechin-3-gallate. Drug Metab Dispos 2006, 34:2111-2116.
105. Lee M.J., Maliakal P., Chen L., Meng X., Bondoc F.Y., Prabhu S., et al. Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability. Cancer Epidemiol Biomarkers Prev 2002, 11:1025-1032.
106. Lu H., Meng X., Li C., Sang S., Patten C., Sheng S., et al. Glucuronides of tea catechins: enzymology of biosynthesis and biological activities. Drug Metab Dispos 2003, 31:452-461.
107. Dube A., Nicolazzo J.A., Larson I. Chitosan nanoparticles enhance the intestinal absorption of the green tea catechins (+)-catechin and (-)-epigallocatechin gallate. Eur J Pharm Sci 2010, 41:219-225.
108. Hu B., Ting Y., Yang X., Tang W., Zeng X., Huang Q. Nanochemoprevention by encapsulation of (-)-epigallocatechin-3-gallate with bioactive peptides/chitosan nanoparticles for enhancement of its bioavailability. Chem Commun (Camb) 2012, 48:2421-2423.
109. Vyas S., Sharma M., Sharma P.D., Singh T.V. Design, semisynthesis, and evaluation of O-acyl derivatives of (-)-epigallocatechin-3-gallate as antitumor agents. J Agric Food Chem 2007, 55:6319-6324.
110. Tanaka H., Miyoshi H., Chuang Y.C., Ando Y., Takahashi T. Solid-phase synthesis of epigallocatechin gallate derivatives. Angew Chem Int Ed Engl 2007, 46:5934-5937.
111. Lambert J.D., Kim D.H., Zheng R., Yang C.S. Transdermal delivery of (-)-epigallocatechin-3-gallate, a green tea polyphenol, in mice. J Pharm Pharmacol 2006, 58:599-604.
112. Wang P., Heber D., Henning S.M. Quercetin increased bioavailability and decreased methylation of green tea polyphenols in vitro and in vivo. Food Funct 2012, 635-642.